(1) the federal government indicates that the federal government will withdraw all federal funds from a health care facility for allowing amygdalin (laetrile) to be used within the facility; and

(2) providing or allowing use of amygdalin (laetrile) within the facility would jeopardize the receipt of:

(A) federal funds for reimbursement for Medicare or Medicaid for all persons within the facility; or

(B) construction funds provided by the federal government under the Hill-Burton Hospital Construction Program (42 U.S.C. § 291 et seq.) or under Title XVI of the Public Health Services Act (42 U.S.C. §§ 300q–300t);

the hospital or other health care facility may prohibit the use of amygdalin (laetrile) within the hospital or facility.

[Pre-1993 Recodification Citation: 16-8-8-7(b).]

As added by P.L.2-1993, SEC.25.